Phaseline

Targets › SLC22A12

SLC22A12 (Solute carrier family 22 member 12): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 2 Phase 3, 2 Phase 2, 1 Phase 4; Metabolic and endocrine, Cardiovascular; next expected readout Jul 2027.

Electroneutral antiporter that translocates urate across the apical membrane of proximal tubular cells in exchange for monovalent organic or inorganic anions. Involved in renal reabsorption of urate and helps maintaining blood levels of uric acid. (UniProt, Q96S37)

Open in Phaseline: the race on SLC22A12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Crystalys TherapeuticsDotinurad
Solute carrier family 22 member 12 inhibitor
SLC22A12Phase 3Gout; Tophaceous Gout; Hyperuricemia or GoutJul 2027
Jiangsu HengRui MedicineShr-4640 (SHR4640)
Solute carrier family 22 member 12 inhibitor
SLC22A12Phase 2Primary Gout and HyperuricemiaJul 2027

Conditions

Gout (2) Tophaceous Gout (1) Hyperuricemia or Gout (1) Primary Gout and Hyperuricemia (1)

Modalities

small molecule (2)

Companies

Crystalys Therapeutics (1) Jiangsu HengRui Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.